ImageneBio (IMA) Change in Accured Expenses (2020 - 2025)

ImageneBio has disclosed Change in Accured Expenses across 6 years of filings, most recently posting -$6.8 million for Q3 2025.

• Change in Accured Expenses for Q3 2025 came in at -$6.8 million, down 243.49% year-over-year; the trailing twelve-month figure through Sep 2025 was -$11.7 million (down 279.44% YoY), and the FY2024 annual result was -$2.5 million, up 67.57% from the prior year.
• Change in Accured Expenses came in at -$6.8 million for Q3 2025 at ImageneBio, down from -$2.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.8 million in Q3 2024 to a low of -$6.8 million in Q3 2025.
• The 5-year median for Change in Accured Expenses is -$1.5 million (2022), against an average of -$871631.6.
• Across the five-year window, Change in Accured Expenses jumped 9480.0% in 2021 and sank 301.37% in 2023, its largest moves.
• ImageneBio's Change in Accured Expenses stood at $1.7 million in 2021, then plunged by 134.57% to -$586000.0 in 2022, then tumbled by 301.37% to -$2.4 million in 2023, then grew by 25.47% to -$1.8 million in 2024, then sank by 289.39% to -$6.8 million in 2025.
• The last three Change in Accured Expenses figures came in at -$6.8 million (Q3 2025), -$2.8 million (Q2 2025), and -$306000.0 (Q1 2025), per Business Quant data.